ID

41070

Descripción

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome; ODM derived from: https://clinicaltrials.gov/show/NCT01289457

Link

https://clinicaltrials.gov/show/NCT01289457

Palabras clave

Versiones (1)
  1. 19/6/20 19/6/20 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

19 de junio de 2020

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Leukemia NCT01289457

Inglés

Eligibility Leukemia NCT01289457

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT01289457
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. sign an irb-approved informed consent document.
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
2. age 18 to 60. patients above the age of 60 only with principal investigator (pi) approval
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
3. diagnosis of newly diagnosed aml [other than acute promyelocytic leukemia (apl)] or high-risk (intermediate-2 or high by ipss or > 10% blasts, including cmml) mds. prior therapy with hydrea and the use of a single or a two day dose of cytarabine (up to 3 g/m2) for emergency use up to 24 hours prior to start of study therapy is allowed. prior therapy for mds or other ahd is not allowed.
Descripción

Leukemia, Myelocytic, Acute | Exception Acute Promyelocytic Leukemia | High risk MYELODYSPLASTIC SYNDROME IPSS | Blasts Percentage | Leukemia, Myelomonocytic, Chronic | Hydrea | Cytarabine Dose U/day

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023467
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0023487
UMLS CUI [3,1]
C4319571
UMLS CUI [3,2]
C3463824
UMLS CUI [3,3]
C2827405
UMLS CUI [4,1]
C0368761
UMLS CUI [4,2]
C0439165
UMLS CUI [5]
C0023480
UMLS CUI [6]
C0591617
UMLS CUI [7,1]
C0010711
UMLS CUI [7,2]
C0178602
UMLS CUI [7,3]
C0456683
4. ecog performance status of </= 3 at study entry.
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
5. organ function as defined below (unless due to leukemia): serum creatinine </= 3 mg/dl total bilirubin </= 2.5 mg/dl , alt (sgpt) </= 3 * uln or </= 5 * uln if related to disease.
Descripción

Organ function | Exception Due to Leukemia | Creatinine measurement, serum | Serum total bilirubin measurement | Alanine aminotransferase measurement | Relationship Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0678852
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0678226
UMLS CUI [2,3]
C0023418
UMLS CUI [3]
C0201976
UMLS CUI [4]
C1278039
UMLS CUI [5]
C0201836
UMLS CUI [6,1]
C0439849
UMLS CUI [6,2]
C0012634
6. women of childbearing potential must have a negative serum or urine pregnancy test within 7 days and must agree to practice acceptable contraceptive methods. men must agree not to father a child and agree to use a condom if his partner is of child bearing potential.
Descripción

Childbearing Potential Serum pregnancy test negative | Childbearing Potential Urine pregnancy test negative | Childbearing Potential Contraceptive methods | Gender Preventing Reproduction | Gender Use of Condom | Partner Childbearing Potential

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0430061
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0430057
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0700589
UMLS CUI [4,1]
C0079399
UMLS CUI [4,2]
C1292733
UMLS CUI [4,3]
C0035150
UMLS CUI [5,1]
C0079399
UMLS CUI [5,2]
C1524063
UMLS CUI [5,3]
C0009653
UMLS CUI [6,1]
C0682323
UMLS CUI [6,2]
C3831118
7. cardiac ejection fraction >/= 40% (by either cardiac echo or muga scan). documentation of recent (</= 6 months from screening) outside reports is acceptable.
Descripción

Cardiac ejection fraction Echocardiography | Cardiac ejection fraction MUGA scan

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0232174
UMLS CUI [1,2]
C0013516
UMLS CUI [2,1]
C0232174
UMLS CUI [2,2]
C0521317
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. breast feeding females
Descripción

Breast Feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006147
2. patients with uncontrolled active infections (viral, bacterial, and fungal are not eligible).
Descripción

Communicable Diseases Uncontrolled | Virus Diseases | Bacterial Infections | Mycoses

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205318
UMLS CUI [2]
C0042769
UMLS CUI [3]
C0004623
UMLS CUI [4]
C0026946
3. patients with active secondary malignancy will not be eligible.
Descripción

Secondary Malignant Neoplasm

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3266877
Volver a la parte superior de la página

Similar models

Eligibility Leukemia NCT01289457

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility Leukemia NCT01289457
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
1. sign an irb-approved informed consent document.
boolean
C0021430 (UMLS CUI [1])
Age
Item
2. age 18 to 60. patients above the age of 60 only with principal investigator (pi) approval
boolean
C0001779 (UMLS CUI [1])
Leukemia, Myelocytic, Acute | Exception Acute Promyelocytic Leukemia | High risk MYELODYSPLASTIC SYNDROME IPSS | Blasts Percentage | Leukemia, Myelomonocytic, Chronic | Hydrea | Cytarabine Dose U/day
Item
3. diagnosis of newly diagnosed aml [other than acute promyelocytic leukemia (apl)] or high-risk (intermediate-2 or high by ipss or > 10% blasts, including cmml) mds. prior therapy with hydrea and the use of a single or a two day dose of cytarabine (up to 3 g/m2) for emergency use up to 24 hours prior to start of study therapy is allowed. prior therapy for mds or other ahd is not allowed.
boolean
C0023467 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0023487 (UMLS CUI [2,2])
C4319571 (UMLS CUI [3,1])
C3463824 (UMLS CUI [3,2])
C2827405 (UMLS CUI [3,3])
C0368761 (UMLS CUI [4,1])
C0439165 (UMLS CUI [4,2])
C0023480 (UMLS CUI [5])
C0591617 (UMLS CUI [6])
C0010711 (UMLS CUI [7,1])
C0178602 (UMLS CUI [7,2])
C0456683 (UMLS CUI [7,3])
ECOG performance status
Item
4. ecog performance status of </= 3 at study entry.
boolean
C1520224 (UMLS CUI [1])
Organ function | Exception Due to Leukemia | Creatinine measurement, serum | Serum total bilirubin measurement | Alanine aminotransferase measurement | Relationship Disease
Item
5. organ function as defined below (unless due to leukemia): serum creatinine </= 3 mg/dl total bilirubin </= 2.5 mg/dl , alt (sgpt) </= 3 * uln or </= 5 * uln if related to disease.
boolean
C0678852 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0023418 (UMLS CUI [2,3])
C0201976 (UMLS CUI [3])
C1278039 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
C0439849 (UMLS CUI [6,1])
C0012634 (UMLS CUI [6,2])
Childbearing Potential Serum pregnancy test negative | Childbearing Potential Urine pregnancy test negative | Childbearing Potential Contraceptive methods | Gender Preventing Reproduction | Gender Use of Condom | Partner Childbearing Potential
Item
6. women of childbearing potential must have a negative serum or urine pregnancy test within 7 days and must agree to practice acceptable contraceptive methods. men must agree not to father a child and agree to use a condom if his partner is of child bearing potential.
boolean
C3831118 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0430057 (UMLS CUI [2,2])
C3831118 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C0079399 (UMLS CUI [4,1])
C1292733 (UMLS CUI [4,2])
C0035150 (UMLS CUI [4,3])
C0079399 (UMLS CUI [5,1])
C1524063 (UMLS CUI [5,2])
C0009653 (UMLS CUI [5,3])
C0682323 (UMLS CUI [6,1])
C3831118 (UMLS CUI [6,2])
Cardiac ejection fraction Echocardiography | Cardiac ejection fraction MUGA scan
Item
7. cardiac ejection fraction >/= 40% (by either cardiac echo or muga scan). documentation of recent (</= 6 months from screening) outside reports is acceptable.
boolean
C0232174 (UMLS CUI [1,1])
C0013516 (UMLS CUI [1,2])
C0232174 (UMLS CUI [2,1])
C0521317 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Breast Feeding
Item
1. breast feeding females
boolean
C0006147 (UMLS CUI [1])
Communicable Diseases Uncontrolled | Virus Diseases | Bacterial Infections | Mycoses
Item
2. patients with uncontrolled active infections (viral, bacterial, and fungal are not eligible).
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0042769 (UMLS CUI [2])
C0004623 (UMLS CUI [3])
C0026946 (UMLS CUI [4])
Secondary Malignant Neoplasm
Item
3. patients with active secondary malignancy will not be eligible.
boolean
C3266877 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial